Koji Fukuda

8PUBLICATIONS
17CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 02, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.

|Jan 18, 2026
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.

Yuya Murase, Shigeki Nanjo, Sachiko Arai

|Jan 12, 2026
LEAP-008: pembrolizumab plus lenvatinib after immunotherapy in non-small cell lung cancer.

Koji Fukuda

|Nov 09, 2025
MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.

Shigeki Sato, Neval Yilmaz, Sachiko Arai

|Apr 01, 2022
Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.

Chiaki Suzuki, Akihiro Nishiyama, Sachiko Arai

|Mar 01, 2022
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.

Naohiro Yanagimura, Shinji Takeuchi, Koji Fukuda

Pageof 2

Frequent Collaborators

5 joint publications

Seiji Yano

2 joint publications

Akihiro Nishiyama

2 joint publications

Shinji Takeuchi

2 joint publications

Hiroshi Kotani